{"disease":{"id":"cutaneous-melanoma","name":"cutaneous melanoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04778449","title":"Quality of Life, Lifestyle, and Psychosocial Factors in Patients With Melanoma","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04789421","title":"Advanced Non-invasive Diagnostics for Early Cutaneous Tumor Diagnosis, Clinical-therapeutic and Economic Management","phase":"NA","overall_status":"COMPLETED","enrollment_count":3248,"lead_sponsor_name":"Azienda Ospedaliero-Universitaria di Modena","has_results":false},{"nct_id":"NCT03860883","title":"Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma","phase":"NA","overall_status":"RECRUITING","enrollment_count":2998,"lead_sponsor_name":"Melanoma and Skin Cancer Trials Limited","has_results":false},{"nct_id":"NCT01274338","title":"Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1673,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01511913","title":"A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma","phase":"","overall_status":"COMPLETED","enrollment_count":1411,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT02506153","title":"Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1301,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03677739","title":"Young Melanoma Family Facebook Intervention or Healthy Lifestyle Facebook Intervention in Improving Skin Examination in Participants With Melanoma and Their Families","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1160,"lead_sponsor_name":"Rutgers, The State University of New Jersey","has_results":false},{"nct_id":"NCT06673095","title":"Narrow Excision Versus Wide Excision for the Treatment of Adults With Invasive Cutaneous Melanoma, ICEMAN Trial","phase":"NA","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT01989572","title":"Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":815,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03819296","title":"Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02339571","title":"A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":600,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04593277","title":"Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":549,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT06075524","title":"Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04792463","title":"Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Mohamed Abdel-Rahman","has_results":false},{"nct_id":"NCT00341939","title":"Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data","phase":"","overall_status":"COMPLETED","enrollment_count":484,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06967961","title":"Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers","phase":"NA","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"Institut Claudius Regaud","has_results":false},{"nct_id":"NCT07068074","title":"A Randomized Phase III Study of Management of Treatment Naive Primary Melanoma in Elderly Patients","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":428,"lead_sponsor_name":"Eastern Cooperative Oncology Group","has_results":false},{"nct_id":"NCT01763164","title":"Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":402,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT02385214","title":"MelmarT Melanoma Margins Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":400,"lead_sponsor_name":"Melanoma and Skin Cancer Trials Limited","has_results":false},{"nct_id":"NCT07361666","title":"Impact of Preoperative High-Frequency Ultrasound Cutaneous Lesion Extent Assessment on Excision Margin Positivity in Head and Neck Skin Cancer, and the Relationship Between Preoperative Assessment Methods, Inadequate Excision Margins, and Tumor Recurrence","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":400,"lead_sponsor_name":"Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji","has_results":false},{"nct_id":"NCT03663647","title":"Advanced Melanoma in Russian Experience","phase":"","overall_status":"COMPLETED","enrollment_count":382,"lead_sponsor_name":"MelanomaPRO, Russia","has_results":false},{"nct_id":"NCT05669430","title":"A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":365,"lead_sponsor_name":"GV20 Therapeutics","has_results":false},{"nct_id":"NCT05824975","title":"A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":358,"lead_sponsor_name":"GI Innovation, Inc.","has_results":false},{"nct_id":"NCT03947385","title":"Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":336,"lead_sponsor_name":"IDEAYA Biosciences","has_results":false},{"nct_id":"NCT03698019","title":"A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":313,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT07148245","title":"Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT02196181","title":"Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":280,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02224781","title":"Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":267,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT07259304","title":"Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors","phase":"","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT07519655","title":"Phase 1 Study of PF-08046033 in Advanced Solid Tumors","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":250,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT01134614","title":"Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":245,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03611868","title":"A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":230,"lead_sponsor_name":"Ascentage Pharma Group Inc.","has_results":false},{"nct_id":"NCT03114319","title":"Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":227,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT02419495","title":"Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":221,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04067960","title":"Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":197,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT01693068","title":"Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":194,"lead_sponsor_name":"EMD Serono","has_results":true},{"nct_id":"NCT04830124","title":"Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":173,"lead_sponsor_name":"Mural Oncology, Inc","has_results":false},{"nct_id":"NCT01950390","title":"Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":169,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06090266","title":"A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":168,"lead_sponsor_name":"OncoResponse, Inc.","has_results":false},{"nct_id":"NCT02791334","title":"A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":164,"lead_sponsor_name":"Eli Lilly and Company","has_results":false},{"nct_id":"NCT03761017","title":"MGD019 DART® Protein in Unresectable/Metastatic Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":162,"lead_sponsor_name":"MacroGenics","has_results":false},{"nct_id":"NCT05267626","title":"Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":159,"lead_sponsor_name":"Aulos Bioscience, Inc.","has_results":false},{"nct_id":"NCT04462406","title":"Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":150,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT06157099","title":"Atorvastatin for Preventing Disease Metastasis in Patients With Resected High-Risk Stage IIA, IIB, or IIIA Melanoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":150,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT05136196","title":"BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05340543","title":"Ex-vivo Examination of Excisions of Skin Tumors by Confocal Optical Coherence Tomography (LC-OCT) With Integrated Dermoscopy and Comparison With Histology (DERMOCTAV)","phase":"","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"Ramsay Générale de Santé","has_results":false},{"nct_id":"NCT02304458","title":"Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":140,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04254107","title":"A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":133,"lead_sponsor_name":"Seagen Inc.","has_results":false},{"nct_id":"NCT05269381","title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04990726","title":"Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":126,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}